Navigation Links
Small Business Innovation Research Program Awards Grant to Biomoda
Date:6/25/2008

Company developing proposals to fund clinical studies for early detection

of lung cancer

ALBUQUERQUE, N.M., June 25 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), a development stage medical diagnostics company, announced it has received a grant from the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (SBTT) seed grant programs to develop proposals for funding of clinical studies using its proprietary testing technology for detection of early lung cancer.

"We're very enthusiastic about the opportunity this capital offers for continued development of various aspects of our portfolio of non-invasive, early stage cancer detection technologies," said Biomoda Government Affairs Advisor Bruce Donisthorpe. "The funding further validates the potential of our innovative technology, particularly the broad-scale benefits expected to accrue from its commercialization."

The SBIR and SBTT's Phase 0 Program provides technology businesses with the opportunity to propose innovative ideas that match research and development needs of 11 participating federal agencies, including the Departments of Homeland Security, Agriculture, Commerce, Defense, Education, Energy, Transportation, Health and Human Services, National Aeronautics and Space Administration, Environmental Protection Agency, and the National Science Foundation.

Biomoda's technology is designed for early lung cancer screening of large populations at a reasonable cost. With the technology, clinicians can identify cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells glow red under fluorescent light and can be detected under a microscope.

Earlier this year, Biomoda and the New Mexico Institute of Mining and Technology announced their partnership with the New Mexico Department of Veterans Services to conduct a $350,000 clinical study using Biomoda's proprietary testing technology for detection of early lung cancer in the state's veterans. The New Mexico state legislature recently allocated an additional $1.3 million in funding.

Lung cancer claims more lives than any other cancer. The expected five- year survival rate for all patients diagnosed with lung cancer is 15 percent; the five-year survival rate for cases detected when the disease is still localized is 50 percent. Presently, only 16 percent of lung cancer cases are diagnosed at this early stage.

Biomoda's technology was originally developed at Los Alamos National Laboratory.

Contact: John Cousins

505-821-0875

investor@biomoda.com

Forward-Looking Statements

All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of BIOMODA's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. BIOMODA, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in BIOMODA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
2. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Albemarle Optimizes Smallpox Drug Candidate for SIGA
5. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
6. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
7. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
8. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
9. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
11. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016 Wegener Polyangiitis - ... Markets Direct,s, ,Wegener Polyangiitis - Pipeline Review, H2 ... therapeutic pipeline. This report provides comprehensive information ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Identifying and Commercializing First-in-Class Innovation ... disorder associated with chronic inflammation of the airways ... of COPD symptoms make the disease one of ... cause of death in the world. COPD is ...
(Date:2/4/2016)... 4, 2016 In response to the opioid abuse ... Commissioner for Medical Products and Tobacco, along with other FDA ... agency,s approach to opioid medications. The plan will focus on ... in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ensure that ...
Breaking Medicine Technology:
(Date:2/5/2016)... Ontario (PRWEB) , ... February 05, 2016 , ... After ... Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to ... Scarborough Hospital. He successfully completed his first three-year term as chief and began a ...
(Date:2/5/2016)... , ... February 05, 2016 , ... The American public ... such water may be safer than regular municipal or well water. The recent experience ... host Sharon Kleyne, could go a long way toward increasing public acceptance of recycled ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot ... 2015 Best in KLAS: Software & Services for HIT Implementation Support & Staffing ... report independently ranks vendor performance by healthcare executives, managers and clinicians representing over ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to ... a complete range of oral health care, including general dentistry, cosmetic treatments, periodontics, ...
(Date:2/5/2016)... ... February 05, 2016 , ... California Mobile Kitchens ... debut of their latest mobile kitchen model, featuring customizable stainless steel interiors and ... commercial kitchens for use anywhere in the U.S. Many of their units can ...
Breaking Medicine News(10 mins):